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Platelet aggregation This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside
triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosph odiesterase), 50-nucle-
otidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the proﬁle of 
platelet aggregation. Animals were divided into ﬁve groups: I (control); II (oil); III (caffeic acid 10 mg/kg);
IV (caffeic acid 50 mg/kg); and V (caffeic acid 100 mg/kg). Animals were treated with caffeic acid diluted 
in oil for 30 days. In platelets, caffeic acid decreased the ATP hydrolysis and increased ADP hydrolysis in 
groups III, IV and V when compared to control (P < 0.05). The 50-nucleotidase activity was decreased, 
while E-NPP and ADA activities were increased in platelets of rats of groups III, IV and V (P < 0.05). Caffeic 
acid reduced signiﬁcantly the platelet aggregation in the animals of groups III, IV and V in relation to 
group I (P < 0.05). In lymphocytes, the NTPDase and ADA activities were increased in all groups treated 
with caffeic acid when compared to control (P < 0.05). These ﬁndings demonstrated that the enzymes 
were altered in tissues by caffeic acid and this compound decreased the platelet aggregation suggesting 
that caffeic acid should be considered a potentially therapeutic agent in disorders related to the puriner- 
gic system. 
 2013 Elsevier Ltd. Open access under the Elsevier OA license. 1. Introduction 
Adenine nucleotides (ATP, ADP) and nucleoside adenosin e rep- 
resent an important class of extracellular molecule s involved in the 
modulation of signaling pathways crucial for the normal function- 
ing of vascular and immune systems (Yegutkin, 2008 ). In the vas- 
cular system, ADP and adenosine modulate the processes linked 
to vascular inﬂammation and thrombosis exerting various effects 
in platelets (Soslau and Youngprapa korn, 1997; Gachet, 2001 ). In 
addition, it is well established that ATP acts through speciﬁc cell 
receptors and is involved in pro-inﬂammatory functions such as 
stimulation and proliferation of lymphocytes and cytokine release, 
while adenosin e exhibits potent anti-inﬂammatory and immuno- 
suppressive actions (Dwyer et al., 2007; Gessi et al., 2007 ).Signaling events induced by extracellular adenine nucleotides 
and nucleosides are tightly regulated by cell surface ectoenzymes 
known as ectonucle otidases. The most relevant ecto-enzymes in- 
volved in adenine nucleotid e extracellular hydrolysi s are NTPDase 
(ecto-nucleoside triphosphate diphosph ohydrolase), ecto-NPPs 
(ecto-nucleotide pyrophosph atase/phosp hodiesterase), ecto-5 0-
nucleotid ase, and adenosin e deaminase (ADA) (Robson et al., 
2006). NTPDase hydrolyzes ATP and ADP to AMP, while E-NPP en- 
zymes are responsible for hydrolyzing 50-phosphod iester bonds in 
nucleotid es and their derivatives, resulting in the production of 
monophos phate nucleotide. AMP resulting from the action of 
NTPDase and E-NPP is subsequent ly hydrolyzed to adenosine by 
ecto-50-nucleoti dase (Colgan et al., 2006; Strater, 2006 ). The 
resultant adenosin e can be inactivated through the action of 
ADA, which catalyzes the irreversible deamination of adenosine 
to inosine. 
Together , these enzymes constitute a highly reﬁned system for 
the regulatio n of nucleotide mediated signaling, controlling the 
rate, degradation and nucleoside formatio n. As a consequence of 
their key physiolog ical role, ectonucleotida ses have been studied 
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2005a, 2005b; Spanevello et al., 2009; Thomé et al., 2012 ). Of 
particular importance , studies from our laboratory have also dem- 
onstrated that natural substances such as resveratrol and curcumin 
altered ectonucleoti dase activities in different tissues, demonstrat- 
ing that phenolic compounds may interfere in the purinergic 
signaling (Schmatz et al., 2009; Jaques et al., 2011 ).
Caffeic acid (3,4-dihydroxy cinnamic acid) is a phenolic com- 
pound naturally found in several fruits, vegetables and herbs, such 
as coffee, artichoke, pear, basil, thyme, oregano, and apple (Clifford,
1999). Caffeic acid is known to have a broad spectrum of pharma- 
cological activities including anti-inﬂammatory, antioxidant ,
immunomo dulatory and neuropro tective (Chan and Ho, 1997; 
Chung et al., 2004; Tanaka et al., 1993; Ban et al., 2006 ). The mech- 
anisms involved in these beneﬁcial properties of caffeic acid have 
not yet been fully understood . In addition, there is no evidence 
on the effects promoted by caffeic acid on purinergic signaling 
parameters.
Therefore, considering the beneﬁcial activities of caffeic acid on 
human health and the importance of ectonucleotida ses, the aim of 
this study was to evaluate changes in the adenine nucleotide 
hydrolysis promoted by ectonucleoti dases in platelets and lym- 
phocytes of rats after treatment with caffeic acid, as well as to 
investigate the effects of this compound on the proﬁle platelet 
aggregation .2. Materials and methods 
2.1. Materials 
Nucleotides, Trizma Base, Ficcoll, Adenosine and caffeic acid were purchased 
from Sigma Chemical Co. (St. Louis, MO, USA). Clopidogrel was obtained from Ger- 
med Farmacêutica LTDA (Hortolôndia, SP, Brazil). All other reagents used in the 
experiments were of analytical grade and of the highest purity. 2.2. Animals 
Adult male Wistar rats (70–90 days, 220–300 g) were obtained from the Central 
Animal House of Federal University of Santa Maria (UFSM). Animals were main- 
tained at a constant temperature (23 ± 1 C) on a 12 h light/dark cycle with free ac- 
cess to food and water. Animals were used according to the guidelines of the 
Committee on Care and Use of Experimental Animal Resources, (COBEA) and are 
in accordance with international guidelines. 2.3. Treatment with caffeic acid 
Fifty rats were used in this study. Animals were divided into ﬁve groups 
(n = 10): group I (control saline); group II (canola oil); group III (caffeic acid 
10 mg/kg); group IV (caffeic acid 50 mg/kg); and group V (caffeic acid 100 mg/ 
kg). The caffeic acid was diluted in canola oil and administered via gavage to the 
animals of groups III, IV and V, while animals of group I received saline and group 
II canola oil. Caffeic acid was freshly prepared and administered once a day for 
30 days. After this time, animals were anesthetized and submitted to euthanasia. 
The total blood was collected by cardiac puncture for lymphocytes, platelet separa- 
tion and platelet proﬁle aggregation. 2.4. Platelet preparation 
Platelet-Rich Plasma (PRP) was prepared by the method of Lunkes et al. (2004).
Total blood was collected by cardiac puncture with 0.120 M sodium citrate as anti- 
coagulant and centrifuged at 160 g for 15 min. Next, PRP was centrifuged at 1400 g
for 30 min and washed twice with 3.5 mM HEPES buffer, pH 7.0. The washed plate- 
lets were resuspended in HEPES isosmolar buffer and adjusted to 0.4–0.6 mg of pro- 
tein per milliliter. 2.5. Isolation of lymphocytes 
Lymphocytes were isolated from blood collected with EDTA as anticoagulant 
and separated on Ficoll–Histopaque density gradients as described by Böyum
(1968). Then, lymphocytes were suspended in saline solution and the ﬁnal protein 
concentration was adjusted to 0.1–0.2 mg/mL. 2.6. NTPDase and 50-nucleotidase activity assays 
In platelets, the reaction medium for NTPDase activity containing 5 mM CaCl 2,
100 mM NaCl, 4 mM KCl, 5 mM glucose and 50 mM Tris–HCl buffer, pH 7.4, at a ﬁ-
nal volume of 200 lL was carried out as described by Lunkes et al. (2004). For 50-
nucleotidase, the reaction medium was used as previously described, except that 
5 mM CaCl 2 was replaced by 10 mM MgCl 2.
In lymphocytes, the NTPDase activity was determined as described by Leal et al. 
(2005a,b). The reaction medium contained 0.5 mM CaCl 2, 120 mM NaCl, 5 mM KCl, 
6 mM glicose and 50 mM Tris HCl buffer pH 8.0, at a ﬁnal volume of 200 lL.
In both cases, 20 lL of the enzyme preparation (8–12 lg of protein) was added 
to the reaction mixture and pre-incubated at 37 C. The reaction was initiated by 
the addition of ATP, ADP or AMP. Reactions were stopped by the addition of 10% tri- 
chloroacetic acid (TCA). Released inorganic phosphate (Pi) was assayed by the 
method of Chan et al. (1986) using malachite green as the colorimetric reagent 
and KH 2PO4 as standard. Controls were carried out to correct for non-enzymatic 
hydrolyses of nucleotides by adding platelets after TCA addition. All samples were 
run in triplicate. Enzyme speciﬁc activities were reported as nmol Pi released/min/ 
mg of protein. 
2.7. E-NPP activity assay 
The E-NPP activity from platelets was assessed using p-nitrophenyl 50-thymi-
dine monophosphate (p-Nph-50-TMP) as substrate as described by Fürstenau
et al. (2006). The reaction medium containing 50 mM Tris–HCl buffer, (pH 8.9),
120 mM NaCl, 5.0 mM KCl, 60 mM glucose and 5.0 mM CaCl2 was pre-incubated 
with approximately 20 lg per tube of platelet protein for 10 min at 37 C to a ﬁnal
volume of 200 lL. The enzyme reaction was started by the addition of p-Nph-5 0-
TMP at a ﬁnal concentration of 0.5 mM. After 80 min of incubation, 200 lL NaOH 
0.2 N was added to the medium to stop the reaction. The amount of p-nitrophenol 
released from the substrate was measured at 400 nm using a molar extinction coef- 
ﬁcient of 18.8  103/M/cm. The enzyme activity was expressed as nmol p-nitro- 
phenol released/min/mg protein. 
2.8. ADA activity assay 
The adenosine deaminase activity was measured in lymphocytes and platelets 
using the method of Giusti (1974). The reaction was started by the addition of 
the substrate (adenosine) to a ﬁnal concentration of 21 mmol/L and incubations 
were carried out for 1 h at 37 C. The pH of enzymatic assay of ADA was 6.5. The 
reaction was stopped by adding 106 mmol/L/0.16 mmol/L phenol–nitroprusside/
ml solution. The reaction mixtures were immediately mixed to 125 mmol/L/ 
11 mmol/L alkaline hypochlorite (sodium hypochlorite) and vortexed. Ammonium 
sulfate of 75 lmol/l was used as ammonium standard. The ammonia concentration 
is directly proportional to the absorption of indophenol at 620 nm. The speciﬁc
activity is reported as U/L. One unit (1 U) of ADA is deﬁned as the amount of enzyme 
required to release 1 mmol of ammonia per minute from adenosine at standard as- 
say conditions. 
2.9. Protein determination 
Protein was measured by the method of Bradford (1976) using bovine serum 
albumin as standard. 
2.10. Effects of the caffeic acid on platelet aggregation of rats 
After 30 days of treatment with caffeic acid, the platelet aggregation proﬁle was 
evaluated in the groups I, II, III, IV and V using the method of Born and Cross (1963)
by measuring turbidity with a Chrono-log optical aggregomete (AGGRO/LINK
Model 810-CA software for Windows version 5.1) and using ADP at a concentration 
of 5 lM as agonist. Results are expressed as percentage of aggregation assuming 
that platelet-poor plasma (PPP) represented 100% light transmission and that PRP 
represented 0% light transmission. After the addition of the agonist, the platelet 
shape changed from discoid to irregular and small aggregate form. The intensity 
of the transmitted light increase moderately. As the platelets secrete granule con- 
tents, larger aggregates form, more light cross and the tracing moves toward 
100% light transmittance constituting 100% of platelet aggregation. 
2.11. Effect of caffeic acid associated with clopidogrel in the proﬁle of the platelet 
aggregation of rats 
Clopidogrel is the most popular antiplatelet drug with high efﬁcacy. In this line, 
this experiment was carried out to compare the effects of caffeic acid and clopido- 
grel in vivo in the platelet aggregation of rats. Twenty rats were used in this study. 
Animals were divided into four groups (n = 5): group I (control saline); group II 
(20 mg/kg clopidogrel); group III (caffeic acid 50 mg/kg); and group IV (clopidogrel
20 mg/kg and caffeic acid 50 mg/kg). Clopidogrel was suspended in saline and 
administered by gavage in the animals of groups II and IV. Caffeic acid was diluted 
in canola oil and administered by gavage in the animals of groups III and IV. The 
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consecutively. After this time, animals were anesthetized and submitted to eutha- 
nasia. The total blood was collected by cardiac puncture and the platelet aggrega- 
tion was evaluated as described above using collagen at concentration of 5 and 
7.5 lg/ml as agonist. 
We also evaluated the time for whole blood visual coagulation in all the groups 
of this experiment. Blood was incubated at 30 C and the whole blood coagulation 
was monitored carefully. Results are expressed as time (s) spent in coagulations. 2.12. In vitro effect of caffeic acid in platelet aggregation of human samples 
The sample consisted of 10 healthy subjects (age 20–30 years). All subjects gave 
written informed consent to participate in this study. The Human Ethics and the 
project were approved by the Ethic Committee of the Federal University of Santa 
Maria. Twelve milliliters of blood was collected from each subject and used to eval- 
uate the in vitro effect of the caffeic acid on the platelet aggregation. Caffeic acid was 
diluted in ethanol 30% and tested in the platelet aggregation at the ﬁnal concentra- 
tions of 0, 0.1, 0.25, 0.50, 0.75 and 1.0 mM, using ADP (5 and 7.5 lM) as agonist. 2.13. Statistical analysis 
The statistical analysis used was one-way ANOVA followed by Duncan’s multi- 
ple range tests. P < 0.05 was considered to represent a signiﬁcant difference be- 
tween groups. All data were expressed as mean ± SEM. 3. Results 
The ﬁndings of the present study demonstrat ed that caffeic acid 
altered the ectonucleotida se activities in platelets after treatment 
for 30 days. As can be observed in Fig. 1, caffeic acid decreased 
the ATP hydrolysis in the animals treated with 10 mg/kg 
(39.30%), 50 mg/kg (31%) and 100 mg/kg (33%) when compared 
with the control group (P < 0.05, Fig. 1A). On the other hand, this 
compound caused an increase in the NTPDase activity for ADP 
hydrolysis in platelets of rats treated with 10 mg/kg (22%),
50 mg/kg (34%) and 100 mg/kg (30%) in relation to the control 
group (P < 0.05, Fig. 1B). Similar to the results obtained for ATP 
hydrolysis, the 50-nucleotida se activity was also reduced in the 
groups exposed to caffeic acid (10 mg/kg (39%), 50 mg/kg (44%)
and 100 mg/kg (40%) (P < 0.05, Fig. 1C).
Fig. 1 also shows the effects of the caffeic acid on the E-NPP and 
ADA activities in platelets. Results demonstrated that this com- 
pound increased the E-NPP (10 mg/kg (72%), 50 mg/kg (138%)
and 100 mg/kg (179%)) and ADA activities (10 mg/kg (71%),
50 mg/kg (105%) and 100 mg/kg (148%)) in a dose-depend ent man- 
ner in all the animals treated in relation to the control group 
(P < 0.05, Fig. 1D and E, respectivel y).
In addition, the ﬁndings obtained regarding the aggregation 
proﬁle revealed that the treatment with caffeic acid with 10 mg/ 
kg, 50 mg/kg and 100 mg/kg for 30 days decrease d platelet aggre- 
gation by 39%, 18% and 18%, respectively, using ADP as agonist, 
when compared with the control group (P < 0.05) (Fig. 2).
In the other set of experiments, we compared the effects of 
clopidogrel and caffeic acid in the proﬁle of the platelet aggrega- 
tion of rats. Fig. 3 shows the in vivo effect of caffeic acid and clop- 
idogrel alone or in association on platelet aggregat ion using 
collagen as agonist. When 5 lg/ml collagen was used, we observed 
a decrease in the platelet aggregation in the group treated with 
clopidogrel (20 mg/kg, 70.68%), caffeic acid (50 mg/kg, 67.813%)
and clopidogrel together with caffeic acid (20 mg/kg and 50 mg/ 
kg, respectively, 79.31%) when compared to the control group 
(P < 0.05). When 7.5 lg/ml collagen was used as agonist a decrease 
was also observed in the platelet aggregation in all groups evalu- 
ated. These ﬁndings were similar to results obtained with 5 lg/
ml of collagen (Fig. 3, P < 0.05).
Fig. 4 demonstrates the whole blood visual coagulation time. 
We observed that the coagulation time signiﬁcantly increased with 
clopidogrel (20 mg/kg, 33.02%) caffeic acid (50 mg, 41.59% and clopidogr el together with caffeic acid (20 mg/kg and 50 mg/kg, 
38.650%) when compared to the control group (P < 0.05).
We also evaluated the in vitro effects of caffeic acid on the plate- 
let aggregation of healthy subjects. When ADP (5 lM) was used as 
agonist, caffeic acid inhibited platelet aggregation at the concen- 
trations of 0.25 mM (43%), 0.50 mM (44.04%), 0.75 mM (48%),
and 1.0 mM (50%). The same pattern was observed when ADP 
(7.5 lM) was utilized as agonist. Caffeic acid also inhibited platelet 
aggregat ion at the concentrations of 0.50 mM (26.5%), 0.75 mM 
(32.91%), and 1.0 mM (43.12%) when compared to control groups 
(P < 0.05, Fig. 5).
Treatment for 30 days with caffeic acid also altered the NTP- 
Dase and ADA activities in lymphocytes of rats. The ATP and ADP 
hydrolysi s was increased in the animals treated with 10 mg/kg, 
50 mg/kg and 100 mg/kg of caffeic acid (102%, 118%, 135% and 
35%, 18%, 71%), respectivel y, when compared with the control 
group (P < 0.05) (Fig. 6A and B). Similarly, the ADA activity also 
showed an increase in the lymphocytes of animals treated with 
10 mg/kg (53%), 50 mg/kg (77%) and 100 mg/kg (103%) when com- 
pared with the control group (P < 0.05) (Fig. 6C).
In addition, it is also important to note that controls were per- 
formed to correct for vehicle (canola oil or ethanol) interfere nce. 
No differences between vehicle group and control were observed 
(Fig. 5: ethanol group 30%, and Figs. 1 and 6: oil group).4. Discussion 
The present study was carried out to evaluate the effects of caf- 
feic acid treatment on the ectonucleotida se activities in different 
cells such as platelets and lymphocytes of rats. To the best of our 
knowled ge, there are no studies in literature evaluating the effects 
of caffeic acid on purinergic signaling until now. 
Our results showed that ATP and AMP hydrolysis in platelets 
was decrease d, while ADP hydrolysi s was increased in all groups 
treated with caffeic acid for 30 days (Fig. 1A–C). In addition, E- 
NPP and ADA activity also increased in the platelets of animals 
treated with this compound (Fig. 1D and E). Corroborati ng these 
results, previous studies from our laboratory demonst rated that 
other phenolic compounds such as resveratrol also altered the 
ectonucle otidase activities from platelets (Schmatz et al., 2009 ).
Taken together, these ﬁndings indicated that phenolic compounds 
play an important role in the purinergi c signaling of platelets. 
It has been established that ATP, ADP and adenosin e inﬂuence
vascular tone, cardiac function and platelet aggregat ion (Burn-
stock, 2004 ). ADP acts upon platelets regulating their aggregat ion 
and modifying their shape, while ATP has been postulated to be 
a competitive inhibitor of ADP platelet aggregation (Birk et al., 
2002; Remijin et al., 2002 ). Furthermore, adenosin e produced by 
nucleotid e catabolism is recognized as a vasodilator and inhibitor 
of platelet aggregat ion (Atkinson et al., 2006; Robson et al., 
2006). The metabolism of these extracellular nucleotid es in plate- 
lets occurs by a multienz ymatic system on their surface (Zimmer-
mann, 2001 ). In fact, in the vascular system the NTPDase is 
accepted to be a potent antithromboti c agent because this enzyme 
rapidly metabolizes ADP, terminating further platelet recruitment 
and aggregation (Anfossi et al., 2002; Lunkes et al., 2004 ).
Studies performed with caffeic and 5-caffeoylquini c acids have 
reported a decrease in the risk of inﬂammation and cardiovascu lar 
diseases (Bonita et al., 2007 ). In addition, caffeic acid from Salvia
miltiorrhi za , a traditional Chinese herbal medicine, (Hirose et al., 
1998) has been used extensively for the treatment of coronary ar- 
tery diseases and myocardial infarct (Beyer and Melzig, 2003 ). Our 
ﬁndings suggest that the beneﬁcial effects of caffeic acid in the car- 
diovascu lar diseases could be associated with the modulation of 
adenine nucleotid e hydrolysis in platelets. Firstly, we showed that 
Fig. 1. Effects of the treatment for 30 days with caffeic acid (10, 50 and 100 mg/kg) on NTPDase (A) and (B), 50-nucleotidase (C), E-NPP (D) and ADA (E) activities in platelets of 
rats. Bars represent mean ± SEM. Results are expressed in nmol Pi/min/mg of protein.  Different from control (P < 0.05, with n = 10).
Fig. 2. Percentage of platelet aggregation of rats treated with caffeic acid (10, 50 
and 100 mg/kg) by 30 days, using ADP (5 lM) as agonist. Bars represent mean ± -
SEM.  Indicates statistical differences in relation to the control groups for P < 0.05; 
with n = 5. 
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activities in platelets. Caffeic acid decreased AMP hydrolysis and 
increased the ADA activity (Fig. 1C and E). This alteration could decrease the adenosine levels in the circulation causing vascular 
complicati ons, since adenosine has an important role in preventing 
the thromboti c process. On the other hand, the inhibition of the 
ATP hydrolysis could be important to decrease the ADP extracellu- 
lar levels. Moreove r, the enhancem ent in the ADP hydrolysi s in 
platelets due to caffeic acid plays a crucial role in controlling the 
platelet coagulant status by removing the extracellular ADP, which 
is the main agonist of platelet aggregation .
Reinforcing this hypothesis, we have also observed that treat- 
ment with caffeic acid for 30 days induced a signiﬁcant reduction 
in platelet aggregation in rats (Fig. 2). Similar results were obtained 
in vitro , which showed that this compound also reduced the plate- 
let aggregat ion in humans, using ADP as agonist (Fig. 5). These 
ﬁndings support the opinion that this phenolic compound can be 
associate d with a reduction and prevention of the risk of cardiovas- 
cular diseases by interfering with mechanis ms of platelet aggrega- 
tion induced by ADP. 
Caffeic acid is metabolized after absorption; however, the per- 
centage metabolized or absorbed has not been established in liter- 
ature. Omar et al. (2012) for instance showed that 3% of caffeic acid 
can be detected in plasma after 1 h, while Olthof et al. (2001) dem-
onstrated that a maximum of 95% of the ingested caffeic 
acid (2.8 mmol) was absorbed from the small intestine in humans. 
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Fig. 3. Percentage of platelet aggregation of rats treated with caffeic acid and 
clopidogrel for 13 days, using collagen at the concentrations of 5 and 7.5 lg/ml as 
agonist. Groups: Control, Clopidogrel 20 mg/kg (Clop 20 mg/kg), caffeic acid 50 mg/ 
kg (CA 50 mg/kg), and clopidogrel (20 mg/kg) + caffeic acid (50 mg/kg) (clop 20 mg/ 
kg + CA 50 mg/kg). Bars represent mean ± SEM.  Indicates statistical differences in 
relation to the control group (P < 0.05; with n = 5).
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Fig. 4. Time of blood visual coagulation of rats treated with caffeic acid and 
clopidogrel for 13 days. Groups: Control, Clopidogrel 20 mg/kg (Clop 20 mg/kg),
caffeic acid 50 mg/kg (CA 50 mg/kg), and clopidogrel (20 mg/kg) + caffeic acid 
(50 mg/kg) (clop 20 mg/kg + CA 50 mg/kg). Bars represent mean ± SEM. Results 
were expressed in time spent in second per group.  Indicates statistical differences 
in relation to the control group (P < 0.05; with n = 5).
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Fig. 5. In vitro effects of caffeic acid on platelet aggregation of healthy subjects 
using ADP 5 lM and 7.5 lM as agonist of the aggregation. Bars represent 
mean ± SEM. Results were expressed in percentage of the aggregation.  Indicates 
statistical differences in relation to the control group (P < 0.05; with n = 10).
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caffeic acid) was absorbed from the alimenta ry tract and was pres- 
ent in the rat blood circulation in the form of various metaboli tes. 
They also showed that caffeic acid metabolites found in rat plasma 
were in the form of glucuronide , sulfate, and sulfate/gl ucuronide 
conjugates of caffeic acid or its methylated compound , ferulic acid. 
The absorbed fraction of caffeic acid and its metabolic may in- 
duce biological effects in blood circulation. In relation to our results, 
it is possible that the platelet aggregation or ectonucleoti dase activ- 
ities in vivo could be inﬂuenced by caffeic acid metaboli tes. In this 
line, previous studies demonstrat ed that p-coumaric, caffeic and 
ferulic acid inhibit collagen-induc ed aggregation in human platelets by 50% at concentrations between 478 and 816 lmol (Hubbard et al., 
2003). In addition, the incubation of whole blood with concentr a- 
tions of 100 lmol/L p-couma ric acid, caffeic acid, ferulic acid, 4- 
hydroxyphe nylpropiony, 5-methoxysali cylic acid, and catechol 
inhibited signiﬁcantly the surface of P-selectin expression (marker
platelet activation) (Ostertag et al., 2011 ). Comparing to the study 
of Ostertag et al. (2011), our results suggest that high concentrations 
of caffeic acid are necessary to inhibit the platelet aggregat ion in- 
duced by ADP in vitro (Fig. 5). As concentrations of 0.5–1 mM are un- 
likely to be reached in the circulation, further studies are needed to 
evaluate whether the consumption of caffeic acid at the concentra- 
tion nutritionally attainable may change the proﬁle of platelet 
aggregat ion in humans .
Another important aspect to be discussed is that platelets ex- 
press receptors on their surfaces which play a crucial role in the 
thrombus formation (Hourani, 1996; Hechler et al., 2005 ). Extra- 
cellular nucleotides P2 receptors consist of two classes: P2X, li- 
gand-gated cation channels, classiﬁed in 7 subtypes (P2X1–P2X7)
and P2Y, receptors G protein coupled, classiﬁed in 8 subtypes 
(P2Y1, P2Y 2, P2Y 4, P2Y 6, P2Y 11, P2Y 12, P2Y 13, P2Y 14) (Moheimani
and Jackon, 2012 ). Among these receptors, only P2X 1, P2Y1,
P2Y12, are expressed at signiﬁcant levels in platelets, with the 
P2Y12 expresse d at the highest extent followed by P2X 1 and P2Y 1,
respectively (Moheimani and Jackon, 2012 ). In relation to platelet 
thrombus formatio n, two of the P2Y receptors play an essential 
role: the P2Y 1 initiates platelet activation in response to ADP and 
participa tes in platelet aggregat ion mediated by collagen, while 
stimulati on of the P2Y 12 receptor by ADP completes and ampliﬁes
platelet activation and aggregation (Dorsam and Kunapuli , 2004; 
Moheimani and Jackon, 2012 ).
Fig. 6. Effects of caffeic acid on NTPDase (A and B) and adenosine deaminase (C)
activity on lymphocytes of adult rats treated for 30 days with caffeic acid (10, 50 
and 100 mg/kg). Bars represent mean ± SEM.  Different from control (P < 0.05; with 
n = 10).
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tive metabolites are known as platelet ADP receptor blockers 
P2Y12 (Savi et al., 2006 ). Clopidogrel is the most commonl y pre- 
scribed P2Y 12 blocker and has been shown to be effective in the 
prevention of cardiovascular complications (Pereillo et al., 2002 ).
In this study, we compared the in vivo effects of caffeic acid and 
clopidogrel in platelet aggregation induced by collagen as well as 
the time of coagulation in rats. As shown in Figs. 3 and 4, caffeic 
acid and clopidogrel have similar effects in platelet aggregation 
and in the time of coagulation. Based on this, it is plausible to con- 
sider that caffeic acid also interfere s with the purinoreceptor es 
P2Y1 and P2Y 12. This novel ﬁnding can provide additional mecha- 
nisms by which the antiaggrega nt effects of caffeic acid could be 
mediated.
The following set of experiments was performed in order to 
evaluate the effects of caffeic acid on the ectonucleotida se activity 
from lymphocytes . Our results showed that after 30 days of exposure, the NTPDase and ADA activities were increased in the 
animals treated with 10, 50 and 100 mg/kg of caffeic acid 
(Fig. 6A–C), demonstrat ing that this compound may also be able 
to induce alteration s in the purinergic signaling in immune cells. 
Extracellul ar ATP is involved in proinﬂammatory functions such 
as stimulation and proliferation of lymphocytes and cytokine re- 
lease. These effects of ATP are controlled by the action of ectonu- 
cleotidases , including NTPDase, which is expressed in numerous 
types of immune cells (Dwyer et al., 2007 ). Studies have demon- 
strated that the expression and activity of NTPDase is up-regulate d
in the activated lymphocytes (Zimmerm ann et al., 1998; Pulte 
et al., 2007 ). It has been also reported that besides the catalytic 
property , NTPDase has also an important role in cell adhesion 
and in the control of lymphocy te functions including antigen rec- 
ognition and/or the activation of effector activities of cytotoxic T
cells (Dombrow ski et al., 1995 ). The treatment with caffeic acid 
was able to increase the NTPDase activity in rat lymphocytes .
These effects suggest a modulatory role of caffeic acid on the nucle- 
otidase pathway, which possibly induces a decrease of extracellu- 
lar ATP, representing a mechanism that may help to reduce 
inﬂammation. In fact, literature describes that caffeic acid has 
anti-inﬂammatory properties, and based on this study it is plausi- 
ble to suggest that this effect can be explained, at least in part, by 
the alteration s in the NTPDase activity in lymphocy tes. 
On the other hand, caffeic acid has also increased the ADA activ- 
ity in lymphocy tes. ADA is considered essential for the differentia- 
tion, normal growth and proliferation of lymphocytes (Aldrich
et al., 2000 ). This enzyme catalyzes the deamination of adenosine 
to inosine and closely regulates extracellular concentratio ns of this 
nucleoside (Franco et al., 1997 ). Adenosine is considered the anti- 
inﬂammatory molecule that inhibits the lymphocy te activation 
and decreases the cytokine secretion through A2A receptors (Dom-
browski et al., 1998; Hershﬁeld, 2005 ). In this context, the increase 
in the ADA activity by caffeic acid may lead to a rapid deamina tion 
of adenosine causing a decrease in the extracellul ar levels of this 
molecule , which can affect the sensitivity of receptors (A2A and
A2B) and alter the inﬂammatory responses. 
The changes promote d by caffeic acid on the nucleotide 
hydrolysi s may be possible due to distinct mechanisms. Caffeic 
acid is effective as a free radical scavenging (Gulcin, 2006 ) and 
chelation of metal ions (Psotova et al., 2003 ). Some studies have 
reported that an antioxidant may become a pro-oxidant to accel- 
erate lipid peroxida tion and/or induce DNA damage under spe- 
cial condition s (Yamanak a et al., 1997 ). Polyphenolic 
antioxidant s, such as resveratrol may induce lipid peroxidation 
and/or DNA damage in the presence of cupric ions (Azmi et al., 
2005). In this line, caffeic acid has been reported to induce lipid 
peroxida tion and DNA damage either alone or in the presence of 
copper ions (Yamanaka et al., 1997 ). Bhat et al. (2007) showed
that concentratio ns of 200 and 400 lM of caffeic acid are capa- 
ble of promoting DNA breakage in lymphocy tes. In light of these 
reports, the effect of the caffeic acid associate d with lipid perox- 
idation is able to alter membrane ﬂuidity. This phenomenon 
could partially contribute to explain the alteration s in the ecto- 
nucleotid ases observed in this study. 
Another important aspect to be discussed is that caffeic acid has 
also been reported to chelate metal (Yamanak a et al., 1997 ). This 
effect may be attributed to the presence of a catechol group that 
has two hydroxyl groups attached to its main ring that may pro- 
duce a site for chelation. Based on these observations , we can sup- 
pose that this chelating property of caffeic acid may alter the 
ectonucle otidase activities because divalent cations are required 
for the catalytic function of these enzymes. Reinforcing this 
hypothes is, Da Silva et al. (2006) also suggests that the chelating 
property of ﬂavonoids may diminish NTPDase, 50- nucleotid ase 
and Na +/K+-ATPase activities in cortical membran e preparation. 
J. Anwar et al. / Food and Chemical Toxicology 56 (2013) 459–466 4655. Conclusion 
In conclusion, our results demonstrat ed that caffeic acid alters 
the ectonucleoti dase pathway, modulating the balance in the pur- 
ine levels which can induce relevant effects in the lymphocy tes and 
platelets. Furthermore, caffeic acids also diminished aggregation 
platelet in human and animals. These ﬁndings suggest that caffeic 
acid is a natural and promising compound and further studies have 
to be carried out in order to determine the therapeutic potential of 
the caffeic acid in the purinergi c signaling associate d with immune 
and vascular disorders. Conﬂict of Interest 
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